CN116600826A - 用于治疗/预防缺血性和/或再灌注损伤的vista激动剂 - Google Patents

用于治疗/预防缺血性和/或再灌注损伤的vista激动剂 Download PDF

Info

Publication number
CN116600826A
CN116600826A CN202180084646.0A CN202180084646A CN116600826A CN 116600826 A CN116600826 A CN 116600826A CN 202180084646 A CN202180084646 A CN 202180084646A CN 116600826 A CN116600826 A CN 116600826A
Authority
CN
China
Prior art keywords
vista
agonist
antibody
optionally
iri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180084646.0A
Other languages
English (en)
Chinese (zh)
Inventor
R·J·诺埃勒
N·斯米茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of CN116600826A publication Critical patent/CN116600826A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202180084646.0A 2020-11-04 2021-11-04 用于治疗/预防缺血性和/或再灌注损伤的vista激动剂 Pending CN116600826A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063109584P 2020-11-04 2020-11-04
US63/109,584 2020-11-04
PCT/US2021/058020 WO2022098846A1 (en) 2020-11-04 2021-11-04 Vista agonist for treatment/prevention of ischemic and/or reperfusion injury

Publications (1)

Publication Number Publication Date
CN116600826A true CN116600826A (zh) 2023-08-15

Family

ID=81458372

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180084646.0A Pending CN116600826A (zh) 2020-11-04 2021-11-04 用于治疗/预防缺血性和/或再灌注损伤的vista激动剂

Country Status (8)

Country Link
US (1) US20230399405A1 (enExample)
EP (1) EP4240409A4 (enExample)
JP (1) JP2023550310A (enExample)
KR (1) KR20230142828A (enExample)
CN (1) CN116600826A (enExample)
AU (1) AU2021373781A1 (enExample)
CA (1) CA3197359A1 (enExample)
WO (1) WO2022098846A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024172543A1 (ko) * 2023-02-17 2024-08-22 뉴패스바이오(주) Igsf11-fc 융합 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 자가면역질환 또는 염증성 질환의 예방 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619722B (zh) * 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
CA2884704C (en) * 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
MX2015007446A (es) * 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
WO2017181109A1 (en) * 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof
PE20190115A1 (es) * 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso

Also Published As

Publication number Publication date
EP4240409A1 (en) 2023-09-13
EP4240409A4 (en) 2024-09-18
CA3197359A1 (en) 2022-05-12
US20230399405A1 (en) 2023-12-14
JP2023550310A (ja) 2023-12-01
WO2022098846A1 (en) 2022-05-12
KR20230142828A (ko) 2023-10-11
AU2021373781A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
EP3802606B1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
US20250236669A1 (en) Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
CN110997712B (zh) 特异性结合pd-1的抗体及其使用方法
TW202208429A (zh) 用於治療多發性骨髓瘤之方法
EP3928790A1 (en) Cd3 antigen binding fragment and application thereof
JP7045327B2 (ja) 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
US20200207867A1 (en) Heavy chain antibodies binding to ectoenzymes
KR20240099227A (ko) 항-EGFR 항체, 항-cMET 항체, 항-VEGF 항체, 다중 특이적 항체, 및 이들의 용도
EP4467566A2 (en) Pan elr+ cxc chemokine antibodies
AU2019337394A1 (en) Improved anti-FLT3 antigen binding proteins
WO2023098785A1 (zh) 抗4-1bb抗体及其用途
CN121729428A (zh) α4β7整联蛋白抗体组合物和使用方法
KR20250044359A (ko) 항-ccr8 항체 및 사용 방법
US20230399405A1 (en) Vista agonist for treatment/prevention of ischemic and/or reperfusion injury
WO2022036196A2 (en) Use of vista agonist for treatment/prevention of cytokine storm or crs or sepsis and/or acute or chronic respiratory distress syndrome (rds)
WO2023010483A1 (en) Anti-human cxcr5 antibody and uses thereof
EP4108683A1 (en) Anti-il-2 antibody, and antigen-binding fragment thereof and medical use thereof
EP4178678A1 (en) Mic antibodies and binding agents and methods of using the same
KR20250130296A (ko) 항-ccr8 항체 및 이의 용도
TWI825687B (zh) 抗ｃｘｃｒ２抗體及其用途
US20260102490A1 (en) Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma
US20260098100A1 (en) Il-4r and tslp inhibitors and methods of use thereof
CA3101270C (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
WO2025064951A1 (en) Anti-tumor antibodies
EP4676977A1 (en) Multifunctional antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination